CELL THERAPEUTICS, INC.

Cell Therapeutics, Inc. Announces Pricing of Upsized Public...

Cell Therapeutics, Inc. Announces Pricing of Upsized Public Offering of 9,000,000 Shares of Common Stock

SEATTLE, July 28/PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; Nuovo Mercato) today announced the pricing of the underwritten public offering of 9,000,000 shares of its common stock at a public offering price of USD $4.75 per share. These shares were sold under an existing shelf registration statement. The offering was increased by 1,000,000 shares over the proposed offering announced on July 14, 2004. In connection with this offering, CTI has granted the underwriters an option to purchase up to 1,350,000 additional shares to cover over-allotments. All shares are being sold by CTI.

UBS Securities LLC and CIBC World Markets are acting as joint book-running managers in this offering. WR Hambrecht + Co, LLC, Delafield Hambrecht, Inc. and Punk, Ziegel & Company, L.P. are acting as co-managers. The final prospectus is available from UBS Securities LLC, Attention: Prospectus Department, 299 Park Avenue, New York, NY 10171, phone number: 212-821-3884, or from CIBC World Markets by fax: 212-667-6136 or email: useprospectus@us.cibc.com.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.cticseattle.com.

Web site: http://www.cticseattle.com

Source: Cell Therapeutics, Inc.

CONTACT: investors, Leah Grant of Cell Therapeutics, Inc.,
+1-206-282-7100, or fax, +1-206-272-4010, or invest@ctiseattle.com, or www.cticseattle.com/investors.htm, or Karl Hanks of Cell Therapeutics, Inc. (Europe), +39-026-103-5807, or fax, +39-026-103-5601, or karl.hanks@ctimilano.com

van bovenstaand bericht.

28 jul 04 09:41